Hydergine in senile mental impairment.
Among gerontopsychiatric drugs, Hydergine is pharmacologically characterized by agonist action at central dopamine and serotonin receptors. This review presents a summary of the results obtained with Hydergine in numerous controlled trials in patients with senile mental impairment. Assessment was carried out by means of a rating scale (mainly the Sandoz Clinical Assessment Geriatric, or SCAG, scale), psychometric tests (e.g. the Nuremberg Geriatric Inventory, or NGI), and the EEG. Hydergine also lowers serum prolactin, though a correlation with clinical improvement has not been established as yet. In the discussion, the need for objective, measurable and precise indicators in gerontopsychiatry is stressed.
D000368:Aged; D002986:Clinical Trials as Topic; D004088:Dihydroergotoxine / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004569:Electroencephalography; D006801:Humans; D001523:Mental Disorders / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D011581:Psychological Tests
D004088:Dihydroergotoxine; D011388:Prolactin